Group One Trading, L.P. Tricida, Inc. Transaction History

Group One Trading, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.14 - $12.49 $97,614 - $8.71 Million	697,245 New	697,245 $104,000
Q1 2022 May 12, 2022	SELL	$7.35 - $10.63 $53,552 - $77,450	-7,286 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$4.19 - $9.56 $20,618 - $47,044	4,921 Added 208.08%	7,286 $70,000
Q3 2021 Nov 12, 2021	SELL	$3.56 - $4.64 $3,916 - $5,104	-1,100 Reduced 31.75%	2,365 $11,000
Q2 2021 Aug 10, 2021	SELL	$3.95 - $5.41 $5,925 - $8,115	-1,500 Reduced 30.21%	3,465 $15,000

Q1 2021 May 12, 2021	BUY	$4.52 - $7.8 $22,441 - $38,727	4,965 New	4,965 $26,000
Q4 2020 Feb 10, 2021	SELL	$4.37 - $9.46 $437 - $946	-100 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$8.56 - $26.93 $856 - $2,693	100 New	100 $1,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.